Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [02/14/2019 21:20 PST] Market Maker Surveillance Report. MTFB, Losing Stocks With Lowest Price Friction For Thursday, February 14th 2019
• [02/14/2019 09:52 PST] Motif Bio plc (NASDAQ:MTFB), Down By 100.00% ($11.00) From $11.000 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [02/12/2019 07:36 PST] MTFB Expected to Trade Down After Bearish Patterns Develop
• [02/05/2019 08:24 PST] MTFB Expected to Trade Up After Bullish Patterns Develop
• [01/11/2019 12:05 PST] Motif Bio plc (NASDAQ:MTFB), Up By 100.00% ($8.24) After BUYINS.NET SqueezeTrigger Report Released on Thursday, January 10th 2019 at a Price of $8.240.
• [01/11/2019 12:05 PST] Motif Bio plc (NASDAQ:MTFB), Up By 100.00% ($7.99) After BUYINS.NET SqueezeTrigger Report Released on Tuesday, January 8th 2019 at a Price of $7.990.
• [01/10/2019 10:29 PST] MTFB SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [01/08/2019 08:16 PST] MTFB SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.